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A group of 204 adult patients was entered into a 
prospective. randomized trial comparing FK506/pred-
nisone with FK506lazathioprine/prednisone after re-
nal transplantation between August I, 1991 and Octo-
ber 11. 1992. The purpose of the study was to see if the 
addition of azathioprine would reduce the incidence 
of rejection and improve graft survival. The recipient 
population was unselected. with 61 (30%) patients un-
dergoing retransplantation, 37 (18%) having a panel-
reactive antibody greater than 40%, and 33 (16%) over 
60 years of age. The mean recipient age was 43.8:t13.7 
years (range 17.6-78). The mean donor age was 
34.0±20.1 years (range 0.3-75); 13% of the cadaveric 
kidneys were from pediatric donors less than 3 years 
of age and were transplanted en bloc. The mean cold 
ischemia time was 31.4:t8.4 hr. Living donors were the 
source of 13% of the kidneys. The mean follow-up was 
22:t4 months (range 12-29). Overall one-year actual 
patient survival was 94%. Overall one-year actual graft 
survival was 87(''c, Patients starting on double therapy 
had a one-year actual patient survival of 96% and a 
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one-year actual graft survival of 92%. Patients starting 
on triple therapy had a one-year actual patient sur-
vival of 91% (P=ns compared with double therapy" 
and a one-year actual graft survival of 82% (P<0.02, 
compared with double therapy). Overall results with 
first cadaver transplants included a one-year actual 
patient survival of 94% and one-year actual graft sur-
vival of 88%, with no differences between double and 
triple therapy. The overall incidence of rejection was 
48%, with 54% in the double therapy group and 41% in 
the triple therapy group (P<.07). The incidence of 
steroid·resistant rejection requiring antilymphocyte 
therapy (OKT3 or ATGAM) was 13%. and was not dif· 
ferent between the double and triple therapy groups. 
The mean serum creatinine was 1.8±0.8 mg/dl. The 
mean BUN was 33:t21 mgJdl. with no significant differ-
ence between the therapy groups. The mean serum 
cholesterol was 192:t49 mg/dl. A total of 56% of the 
patients are off prednisone, and 35% of the patients 
are not taking any antihypertensive medications. 
Other complications included cytomegalovirus-14%; 
new·onset diabetes-16% <half of which was revers· 
ible); and posttransplant lymphoproliferative disor· 
der-l%. There was a high incidence of crossover be-
tween the two groups, 27% of the patients in the 
double therapy group requiring the addition of aza· 
thioprine. and 45% of the patients in the triple therapy 
group requiring ita discontinuation (usually tempo-
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rary). These results show that FK506 is an excell~nt 
immunosuppressive agent after renal transpl~ntabon 
and that azathioprine is not routinely effectIve as a 
third agent. A high quality of life resulted from the 
ability to use no (56%) or low-dose maintenance ste-
roids. 
FK506 (Tacrolimus-Prograf) is a new immunosuppressive 
agent (1-3) that has been recently approved by the Food and 
Drug Administration for use after liver transplantation (4-
7). Promising clinical experiences with this drug have also 
been described in heart (8), lung (9), intestine (10), and islet 
(11) transplant patients. In renal transplantation, the initial 
studies. while encouraging, seemed to suggest that FK506 
resulted in equivalent patient and graft survival when com-
pared with cyclosporine-based regimens (5, 12-14), The dif-
ferences were seen in secondary issues, such as an increased 
freedom from chronic steroids, a somewhat lower need for 
antihypertensive medications, and significantly lower serum 
cholesterol levels (13, 14), On the basis of these findings, a 
prospective randomized trial was begun in August 1991, 
comparing two FK506-based regimens-with and without 
azathioprine. The purpose was to see if the addition of aza-
thioprine would help to improve the primary outcomes and 
patient and graft survival, and decrease the incidence of 
rejection. Early reports of this trial suggested that overall 
graft survival under FK506 was improving with experience, 
but that the benefit of azathioprine was unclear (15,16). The 
data presented here reflect a minimum of one year of fol-
low-up in the first 204 patients entered into this randomized 
trial. with actual survival calculations. 
MATERIALS AND METHODS 
Between August I, 1991 and October 11, 1992.204 patients were 
entered into a randomized trial comparing FKS06/prednisone and 
FKS06/azathiopnneiprednisone. Inclusion and exclusion criteria. the 
details of randomization. and the Immunosuppressive protocol have 
heen previously described U5. 16). The patient population was un-
,elected and represented virtually all of the adults undergomg renal 
transplantatIOn alone at the University of Pittsburgh Medical Cen-
ter during this period. There were a high percentage of retransplan-
tations (61 r30o/cll. sensitized recipients (PRA >40%-37 [18%1l. and 
older patients (age >60-33 [l6%1l. There were 28 (14%) black. 4 
(2%) Asian. and 2 (1%) hispaniC recipients. The mean recipient age 
was 43.8::13.7 years (range 17.6-78). and the mean donor age was 
34.0::20.1 years (range 0.3-7S). A total of 178 (87%) transplanta-
tions were With cadaveric kidneys, and 26 (l3,}) were with living-
donor kidneys. Of the cadavenc transplantations. 24 (13%) were 
with pediatnc en bloc kidneys from donors 3 years of age or younger. 
The mean cold ischemia time for the cadavenc cases was 31.4=:8.4 
hr. There were 7 (3%) S-anti~en-match and 13 (S,}) O-antigen-
mismatch cases. 
There were more older patients (>60 years, in the triple therapy 
group 122% vs. 11%. P<.04) and more living-donor cases In the 
double therapy group (18% vs. 8q;.. P<.041. The two groups wpre 
otherwise SImilar with re~ard to donor and recIpIent charactenstics. 
The protocol was reviewed and approved by the Institutional Review 
Board of the University of Pittsburgh. and was renewed on a yearly 
basis. 
Statistical '\fethods. The standard two-sample t test was used to 
test differences in means while differences m proportions were tested 
usin~ Pearson's chi-square test of association. 
Patient surVIVal was calculated from the date of kidney transplan-
tation until death. and graft survival from the date of kidnev trans-
plantatlon untll graft failure. retransplantatlon. or patient death. 
Survival curves were generated using the Kaplan-Meier (product· 
limit) method and were compared using the generalized Wilcoxon 
(Breslow, test. A multivanate Cox's regression analysis was per· 
formed to adjust the relative risk of graft failure between the two 
groups based on age of recipient lover 60 years) and living-donor 
cases. A stepwise procedure was performed to identify high-risk 
patients for graft failure using all available information collected. A 
P value less than .OS was considered statistically signIficant. All 
analyses were performed according to intention-to-treat. unless oth-
erwise stated. 
RESULTS 
The mean follow-up was 22:::4 months (range 12-29). The 
overall actual one-year patient survival was 94%; in the 
double therapy group, it was 96%, and in the triple therapy 
group, it was 91% (Fig. 1; P=0.10l. 
The overall one-year actual graft survival was 87%. In the 
double therapy group, it was 92%, and in the triple therapy 
group, it was 82% (Fig. 2; P<0.02l. For first cadaver trans-
plants, the one-year actual graft survival was 88%; in the 
double therapy group, it was 90'70, and in the triple therapy 
group, it was 87% (P=ns). Comparative one-year actual graft 
survivals in specific subgroups are shown in Table 1. Triple 
therapy was associated with poorer one-year graft survival in 
cadaveric cases, in patients undergoing retransplantation, in 
patients with PRAs >40%, in patients with immediate graft 
function, in patients who experienced rejection, in recipients 
who did not receive pediatric en bloc kidneys, in nonblack 
recipients, and in cases where the donor or the recipient was 
less than 60 years of age. First transplants, living-donor 
cases, patients with PRAs <40%. patients receiving pediatric 
en bloc kidneys, patients experiencing ATN, patients not 
experiencing rejection. black recipients, and donors or recip-
ients over 60 years of age showed no difference between 
double and triple therapy. With regard to specific subgroups. 
the only significant variable was the presence of ATN. which 
was associated with significantly worse one-year graft sur-
vival. In all of the other subgroups. no difference was seen-
i.e .. outcome after retransplantation was similar to that seen 
with first transplants; patients with high PRAs did as well as 
with patients with low PRAs; blacks did as well as non blacks: 
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patients who had rejection were not significantly different 
from patients who did not have rejection: and so on (Table 1l. 
A multivariate analysis was performed. using Cox's pro-
portional hazards model. Two variables were associated with 
an mcreased likelihood of graft failure: the presence of ATN 
(relative nsk 4.32 [95% contidence interval 2.10-8.881. 
P<.OOOl), and initial immunosuppression with triple ther-
apy (relative risk 2.83 [95% contidence interval 1.35-5.931. 
P<.006). 
The mean serum creatinine, calculated creatinine clear-
ance, and BUN were 1.8:!:0.8 mg/dl, 55:!:25 ml/min, and 
33:!:21 mg/dl, and were not significantly different between 
double and triple therapy patients (Table 2), 
The incidence of acute rejection was 48%; in the double 
therapy group it was 54%, and in the triple therapy group it 
was 41%. This difference did not quite reach statistical sig-
nificance (P<.07). The incidence of rejection in specific sub-
groups is shown in Table 3. In cadaveric cases, there was less 
rejection with triple therapy than with double therapy (43% 
vs. 61%, P<.02). In specific subgroups, retransplant patients 
had more rejection than recipients of first transplants; ca-
daveric cases had more rejection than living-donor cases; 
high-PRA patients had more rejection than low-PRA pa-
tients; black patients had more rejection than nonblacks; 
patients with ATN had more rejection than patients without 
ATN. Over 70% of the rejections were responsive to steroids 
and adjustment in the FK506 dosage. Antilymphocyte ther-
apy was needed for steroid-resistant rejection in 13% of pa-
tients; there was no difference between double and triple 
therapy. 
The incidence of initial nonfunction, defined as a lack of 
allograft urine output or a need for dialysis within the first 
week after transplantation, was 38%; in the double therapy 
group it was 41 %, and in the triple therapy group it was 34% 
(P=ns). The incidence of initial nonfunction in specific sub-
groups is shown in Table 4. Not surprisingly, cadaveric re-
cipients had more ATN than living-donor recipients, and 
increasing cold ischemia time was associated with an in-
creasing incidence of ATN. Blacks also had more ATN than 
nonblacks. 
The incidence of cytomegalovirus disease or infection was 
14%; all were treated with gancyclovir. The CMV incidence 
for the 4 different donor/recipient serologic combinations is 
shown in Table 5. The highest incidence, 38%, was in the 
seropositive donor/seronegative recipient group (P<.OOOOll. 
All patients received high-dose acylovir prophylaxis; CMV 
hyperimmune globulin was also given to patients in the se-
ropositive donor/seronegative recipient group. 
The incidence of posttransplant Iymphoproliferative disor-
der (PTLDl was 1% (1 patient in each immunosuppressive 
grOUP). In both cases, the PTLD disappeared with reduction 
of immunosuppression and initiation of gancyclovir therapy, 
and renal function was maintained. In addition, there was 
one case of Kaposi's sarcoma in a patient on triple therapy 
who was lost to follow-up after returning home outside the 
United States. It resolved after discontinuation of immuno-
suppression. but the patient eventually lost her allograft. 
The incidence of new onset diabetes was 16%, 22% in the 
double therapy grouP. and 10% in the triple therapy group 
(P<.04l. Half these patients were able to be weaned off in-
sulin once the FK506 and steroid dosages were reduced-
thus. the incidence of chronic new-onset insulin dependence 
was 8%: 13% in the double therapy group and 4% in the triple 
therapy group (P<.05). 
TABLE 2. Renal function 
Creatinine 
Creatmine clearance 
BUN 
:.!·Druj{ 
1.9:!:O.8 
55:!:24 
:J3:!:22 
3·Druj{ 
1.8:!:O.8 
56:!: 26 
33:!:21 
Total 
1.8:!:O.8 mgJdl 
55:::25 mwdl 
:l:l:!:21 mgJdl 
• 
I 
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Overall 
1st Transplant 
Retransplantation 
Cadaveric 
Living-donor 
PRA <40% 
PRA >40% 
NoATN 
ATN 
Black 
Nonblack 
Donors >60 years 
Donors < 60 years 
Recipients <60 years 
Recipients >60 years 
Overall 
1st Transplant 
Retransplantation 
TABLE 3. Rejection 
2.Drug 3·Drug Total 2 vs. 3 Subgroup 
54% 41% 48% NS 
49% 36% 43% ~p P<.04 
66% 53% 59% NS 
61 % 
22% 
43% 51% P<.02 P<.007 
49% 
80% 
43% 
69% 
85% 
49% 
62% 
53% 
55% 
46% 
25% 23% NS 
35% 43% NS 
64% 70% NS 
34% 39% NS 
54% 62% NS 
67% 75% NS 
37% 43% NS 
50% 57% NS 
40% 46% NS 
45% 50% NS 
27% 33% NS 
TABLE 4. ATN 
P<.002 
P<.OOI 
P<.002 
NS 
NS 
2.Drug 3·Drug Total 2 VS. 3 Subgroup 
41% 34% 38% NS 
37% 31% 34% NS NS 
,'i2% 41% 46% NS 
Cadaveric 48% 37% 42% NS P<.OOI 
o 8% NS Living·donor 11 % 
PRA <40% 40% 
PRA >40% 47% 
Black 54% 
~ onblack :39'7c 
Donors >60 years 54% 
Donors <60 years 399C 
Recipients <- 60 years 42'7c 
Recipients >60 years 36% 
CIT 
29% 35% NS NS 
55% 51% NS 
60% 57% NS P<.03 
30% :;5% NS 
50% :'i2% NS ~p 
:33% :36% NS 
:31 % 37% NS NS 
46% 42% NS 
K~ 12 hr 
·24 hr 
>24 hr 
ll'7c 0 1'\% ~p P<.OOOI 
o 290/c 16% ~p 
16% :]0% :39% NS 
·36 hr 79l'1c S3% 63% :-IS 
Crossover was seen frequently. In the double therapy 
bTTOUP. '27r:'r of patients received azathioprine at one time or 
another. and virtually all of these patients were permanently 
switched to tnple therapy. In the triple therapy group. 45'4- of 
patients were taken off azathioprine at one time or another. 
and 11'7c remain off azathioprine permanently. The main 
reason for conversion from double to triple therapy was re-
jection. and the main reason for conversion from triple to 
double therapy was neutroperua or liver dysfunction. The 
Overall 
--+ 
2·Drug 
12% 
30% 
3% 
11% 
10% 
TABLE 5. CMY 
:)·Drug 
15% 
47% 
8% 
15% 
7% 
Total 
14% 
38% 
6% 
13% 
8% 
2 vs. 3 Subgroup 
NS 
NS 
NS P<.OOOOI 
NS 
NS 
one-year actual patient and graft survivals in patients cur· 
rently on double therapy were 94% and 86%; in patient5 
currently on triple therapy, they were 93% and 88% (P=nsl 
The mean FK506 dosage was 10.3::5.8 mg/day (0.15::0.10 
mg/kg/day) and was not different between the 2 treatment 
groups. The mean FK506 level was 0.88±O.72 ng/ml and was 
also not different between the 2 groups. 
A total of 56% of the patients have been weaned off ste· 
roids. 57% in the double therapy group and 56% in the triple 
therapy group; 5% had steroids withdrawn and then re-
started because of rejection-none of these patients lost their 
allograft. The mean prednisone dose was 3.7::5.6 mg/day; In 
patients still on steroids, it was 7.8::5.7 mg/day. 
A total of 35% of the patients were off antihypertensive 
medications-30% in the double therapy group and 40% in 
the triple therapy group. The mean number of antihyperten. 
sive medications required was 1.0:: 1.0,1.1::1.0 in the double 
therapy group and 0.9::1.0 in the triple therapy group. 
The mean serum cholesterol was 192±49 mgldl, and was 
not different between the two groups. 
DISCUSSION 
Current expectations in renal transplantation are high: 
there is a presumption that no more than 5-10% of patients 
will die within the first year after transplantation, and that 
no more than 15-25% of patients will lose their allograft 
within the first year \ 1 n While these results are not perfect. 
they are considerably better than they were 15 vears al!o 
(18), and represent maturation of a field that bare"ly existed 
35 years ago. However, current outcomes offer little reason 
for complacency, and active investigation of new immunosup-
pressive agents is proceeding around the world. FK506. the 
farthest along of these agents, has already been demon· 
strated to be a superior drug for liver transplantation \ 4 -6. 
7). Experience with kidney transplantation, including the 
data reported here, has suggested improving outcomes with 
FK506, in unselected patients. that equal or surpass the best 
results obtainable with conventional therapy (15. 16). Of 
perhaps hTTeater significance is the ability to withdraw ste· 
roids in more than half the patients. Other trials, from Japan 
and the United States. have demonstrated excellent out-
comes tl9-211. If comparable results are seen with the ongo-
ing Amencan and European multicenter trials. this will con-
firm the utility of FK506 as a formidable addition to the 
immunosuppressive armamentarium in renal transplanta-
tion. 
The goal of the current randomized trial was to assess the 
ability of preemptive azathioprine to reduce the incidence of 
rejection and safely improve graft survival bevond that 
achievable with FK506 and prednisone alone. While the ad-
dition of azathioprine was associated with less rejection. 
February 27. 1995 SHAPIRO ET AL. 489 
particularly in cadaveric recipients. the reduction was not 
significant-and in fact. overall graft survival was worse in 
patients starting on triple therapy. There was a high inci-
dence of crossover in both treatment limbs, but nearly twice 
as many from triple to double as from double to triple ther-
apy. Thus the routine administration of azathioprine as a 
third agent was not advantageous. Nevertheless, about one 
quarter of the patients who self-selected to delayed azathio-
prine were thought to have derived benefit from it. 
The apparent superiority of FK506 and prednisone alone 
and the outstanding results in patients with a higher-than-
average risk profile raises questions about the wisdom of 
polypharmaceutical immunosuppression as complex as in the 
ongoing American multicenter randomized trial comparing 
cyc!osporine and FK-506 for renal transplantation. In these 
trials, a sequential four-drug regimen is being used, begin-
ning with induction antilymphocyte therapy and azathio-
prine. If azathioprine is confirmed to be without value in 
these trials. it may be that one of the new agents on the 
horizon such as mycophenolate mofetil (RS-61443) (22). bre-
quinar (23), rapamycin (24). leflunomide (25), or deoxysper-
gualin (26) will be an effective third agent. It is noteworthy 
that even with cyclosporine convincing controlled studies 
showing the value of triple or quadruple therapy versus 
cyclosporine-prednisone are not available (27-29). 
The side effects of FK506 are similar to those seen with 
cyclosporine. the principal ones being nephrotoxicity (30--34), 
neurotoxicity (35). and diabetogenicity (36). These are all 
dose-related and largely reversible with dose reduction. The 
infectious profile is also similar to that observed in past 
experience (14). although in liver recipients. the mortality 
from infectious complications has been significantly less (7). 
Hirsutism and gingival hyperplasia do not occur with FK506 
(12-]4). The long-term liability of hypercholesterolemia and 
refractory arterial hypertension have been reduced in recip-
ients of various organs-a particular advantage for pediatric 
renal (37. 38) and heart recipients (39). One-third of the 
adults in the present series require no antihypertensive med-
ications. 
Our global assessment is that FK506 is a highly effective 
agent for renal transplant patients. once its nuances have 
been mastered. The addition of azathioprine to the combina-
tion of FK506 and prednisone was not uniformly advanta-
geous. although there are some patients who may have ben-
efited from the secondary use of azathioprine for specific 
indications. Further improvements in the short-term-and 
particularly the long-term-outlook after renal transplanta-
tion may depend more on biologic immune modulation. as 
with the adjuvant administration of donor bone marrow that 
has been reported elsewhere (40). 
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THROMBOXANE SYNTHASE EXPRESSION IN RENAL 
TRANSPLANT PATIENTS WITH REJECTION l 
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Thromboxane synthase (TS) catalyzes the formation 
of thromboxane E~F in monocytest'macrophages, 
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platelets, and various tissues. TxA.z is likely to playa 
role in graft dysfunction due to its vasoconstrictive 
and platelet aggregatory properties, 
We studied the expression of TS in 7 normal native 
kidneys, 29 consecutive renal allograft biopsies (per-
formed for rising serum creatinine, n=23, and delayed 
graft function, n=6), and one transplant nephrectomy 
specimen with severe acute rejection. TS expression 
was determined by immunocytochemistry using a 
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